IL-9 recombinant protein
- Known as:
- Interleukin-9 Rec. protein
- Catalog number:
- BRP1052
- Product Quantity:
- 10 μg
- Category:
- -
- Supplier:
- Biospect
- Gene target:
- IL-9 recombinant protein
Related genes to: IL-9 recombinant protein
- Gene:
- IL9 NIH gene
- Name:
- interleukin 9
- Previous symbol:
- -
- Synonyms:
- IL-9, HP40, P40
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-06-11
- Date modifiied:
- 2016-10-05
Related products to: IL-9 recombinant protein
Related articles to: IL-9 recombinant protein
- Lung cancer is among the most common malignancies globally, exhibiting the greatest rates of incidence and death compared to all other cancers. Cigarette smoking is a significant causal factor in lung cancer; yet the molecular mechanisms via which smoking facilitates lung cancer development remain mainly ambiguous. In this study, we used different concentrations of cigarette smoke extract (CSE) to A549 cells. Compared with the control group, the total STAT3 expression remained basically unchanged. However, we found that phosphorylated STAT3 (p-STAT3), interleukin-9 (IL-9), and miR-155-5p all increased obviously, while the expression of suppressor of cytokine signaling 1 (SOCS1) decreased greatly. Moreover, the epithelial marker E-cadherin was downregulated, while the mesenchymal markers Vimentin and α-SMA were upregulated, indicating the induction of epithelial-mesenchymal transition (EMT). Interventions with STAT3 siRNA, a miR-155-5p inhibitor, or a SOCS1 overexpression plasmid reversed these changes. Similarly, co-treatment with an IL-9-neutralizing antibody attenuated CSE-induced alterations in p-STAT3, SOCS1, miR-155-5p, and EMT markers. In a nude mouse xenograft model, CSE exposure significantly enhanced tumor growth and EMT phenotypes, whereas IL-9 neutralization reduced tumorigenicity of CSE-treated A549 cells. Collectively, these findings demonstrate that cigarette smoke promotes lung cancer progression by inducing EMT through the IL-9-regulated STAT3/miR-155-5p/SOCS1 feedback loop, providing novel mechanistic insight and potential therapeutic targets for smoking-related lung cancer. - Source: PubMed
Publication date: 2026/06/19
Li ZhanLuo YajunLiu XinTan JiangWang HailanLu JiWei WencaiZhang QinshuZhang TingZhang QingbiBai Jun - Systemic lupus erythematosus (SLE) is a progressive antibody-mediated autoimmune disease characterized by systemic immune complex deposition. A subset of SLE patients has elevated CD4+IL-9+ T cells as well as increased levels of secreted interleukin (IL)-9 and IL9 messenger RNA compared with healthy control subjects. However, because IL-9 can have both pro- and anti-inflammatory effects in autoimmune disease, its function in SLE is unclear. We use the MRL/lpr murine model of SLE to demonstrate that IL-9 exhibits protective activity in the early stages of disease. Treatment of these mice with an IL-9 neutralizing antibody from 6 to 12 wk of age results in an expansion of immune cells, leading to exacerbation of disease. In contrast, treatment with anti-IL-9 from 6 to 18 wk of age does not significantly alter disease course compared with isotype control. Anti-IL-9 antibody treatment of these mice results in reduced systemic IL-2 levels, IL-9+ type 2 innate lymphoid cells, and regulatory T cells in the kidney, suggesting an IL-9-dependent suppressive cellular circuit similar to that observed in rheumatoid arthritis. Importantly, supplementation of IL-2 during IL-9 blockade recovers regulatory T cell numbers and limits disease. Together, these data demonstrate an IL-9-dependent suppressive circuit that is evident early in the development of SLE which may be amenable to manipulation to achieve a therapeutic benefit. - Source: PubMed
Krishnan Maya SZhou BaohuaYang DongmingGoncalves Joao IJackson Kaitlyn GXue Gloria RTurner Matthew JKaplan Mark H - Atopic dermatitis (AD) is often associated with ocular surface disease (OSD). Dupilumab, an IL-4Rα inhibitor, is an effective treatment for AD but it sometimes induces dupilumab-associated OSD (DAOSD). DAOSD may associate with a paucity of conjunctival goblet cells or altered immune response; however, the mechanism remains undetermined. Therefore, we aimed to identify ophthalmological alterations and to explore the potential mechanisms of DAOSD in AD patients receiving dupilumab. - Source: PubMed
Publication date: 2026/06/11
Cho Yung-TsuChan Tom CChen Wei-LiChu Hsiao-SangChu Chia-Yu - Tularemia is a rare zoonotic infection with marked geographic clustering and long interepidemic periods. Pediatric data, particularly those on host immune responses during active disease and treatment, remain scarce. The authors aimed to evaluate clinical characteristics and treatment-associated cytokine dynamics in children with tularemia. In the present multicenter prospective study conducted in Türkiye, 40 pediatric patients with laboratory-confirmed tularemia and nine age- and sex-matched healthy controls were enrolled between April 2023 and November 2024. Clinical features, exposure history, and treatment outcomes were recorded. Serum cytokine levels, including interleukin (IL)-6, IL-2, IL-9, IL-5, IL-13, tumor necrosis factor-α, IL-10, interferon (IFN)-γ, IL-4, and IL-22, were measured using a multiplex bead-based assay and compared between patients and controls, between good and poor outcome groups, and longitudinally before and after therapy. A good outcome was defined as complete clinical resolution without suppuration, the need for surgical intervention, or relapse, whereas a poor outcome was defined as clinical nonresolution or progression. A total of 24 (60%) participants had a good outcome, and 16 (40%) had a poor outcome. Although baseline cytokine levels did not differ between groups, paired analyses revealed significant posttreatment reductions in IFN-γ (P = 0.018), IL-6 (P = 0.018), and IL-10 (P = 0.032), consistent with resolution of infection-associated immune activation. A poor outcome was associated with increased exposure to natural water sources and a higher frequency of suppurative lymphadenopathy requiring surgical drainage. Baseline cytokine profiles did not predict treatment response; however, dynamic changes in IFN-γ, IL-6, and IL-10 were associated with clinical recovery. These findings highlight the importance of longitudinal immune monitoring and provide insight into immune dynamics in pediatric tularemia. - Source: PubMed
Publication date: 2026/06/11
Cakici OzlemAykac KubraSeyrek Bera EnesYılmaz İsmail CemDemir Osman OguzEvcili İremCanavar Yıldırım TuğçeYıldırım MuzafferErdeniz Emine HafizeYasar Durmus SevgiSahin AslıhanOcal Demir SevliyaCengiz Ali BulentGürsel MaydaGürsel İhsanOzsurekci Yasemin - Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis. This study evaluates a novel variant of RG-I from chicory root (chRG-I). In a randomized, double-blind, placebo-controlled trial, 55 healthy adults were stratified by habitual fiber intake and baseline levels before receiving 500 mg/day of chRG-I or placebo for four weeks. Primary endpoints included fecal counts. Secondary outcomes assessed fecal metabolites, systemic immune cell activation markers, and gastrointestinal symptoms. To provide mechanistic insights, donor-matched fecal samples were used in fermentation and Caco-2/peripheral blood mononuclear cell co-culture gut barrier models. Supplementation with chRG-I induced a statistically significant bifidogenic effect, with absolute levels peaking at week three, and lower levels of some fecal short-chain fatty acids (SCFA) compared to placebo. However, donor-matched fermentations with chRG-I confirmed robust production of SCFA and reduction of branched-chain fatty acids levels (BCFA). Systemically, chRG-I upregulated HLA-DR expression on myeloid dendritic cells. Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo. In an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21. Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient. - Source: PubMed
Publication date: 2026/05/13
Kerezoudi Evangelia NMcKay SueKurt SetaDe Kreek MaaikeDe Medts JelleVerstrepen LynnGhyselinck JonasMeulebroek Lieven VanCalame WimAlbers RuudMercenier AnnickBrummer Robert JRangel Ignacio